Danahervs.Revvity
DHR vs RVTY · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Danaher is about 11× larger than Revvity by market cap; Danaher trades at the lower P/E (35.9 vs 55.1); year to date, Revvity leads (+27.1% vs −6.0%).
Side by side
| DHR | RVTY | |
|---|---|---|
| Market cap | $144B | $13.1B |
| Price | $215.97 | $124.84 |
| Today | +0.4% | +1.5% |
| Return YTD | −6.0% | +27.1% |
| Return 1Y | +1.6% | +30.6% |
| P/E | 35.9 | 55.1 |
| P/S | 5.7 | 4.5 |
| P/B | 2.7 | 1.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
DanaherDHR
Cytiva supplies the equipment biologics are made with; Cepheid runs molecular diagnostics. Danaher owns both, along with a wider set of life science instruments.
Full DHR profile →RevvityRVTY
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Full RVTY profile →More DHR & RVTY comparisons
Other head-to-heads in the Life science tools segment.
See where DHR and RVTY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →